My guess would be Antares Pharm (ATRS). Teva is currently working on four products in which Antares will provide injectors. It will be cheaper for Teva to own Antares than it will be to pay for all those injectors if the four products launch. EPI pen is one of the products and that will likely turn out to be huge. Has anyone heard when Teva will launch EPI. I know they have to wait until sometime after June 22, 2015
Sentiment: Strong Buy
Whats with all the spam advertisements on this board?
Can you help yourself and everyone else and flag all the spam? I suppose if its flagged enough, itll be removed.
As I said before, the 3 a week dosage that Teva has patent on for next 10 years will negate
the generics..Teva just showed that by raising price twice in last 6 months.
I guess they must get paid to post spam that dilutes the conversation, makes them an obstacle to dialogue, and shows their ignorance of any company's reality. I believe the term is obfuscation. Not a real productive use of anyones time. But somebody must be dumb enough to buy this #$%$.Yahoo must get a kickback or it would have stopped long ago. GLTA (except the spamming losers)
I've been watching people sell Teva from 49.00 to now. Some people can't see the forest because
of the trees. See you at 80 and then a stock split. GL.
At first it was confirmed by a source, now they say two people. Right now just rumors. Possibly Monday someone confirms there is talks. MYL has been getting dumped and on Monday probably dumped more. Would make a TEVA buyout case of MYL stronger but MYL is being hard headed. MYL will need to consolidate as well to stay relevant since everyone else is.
With competition heating up in their main earnings driver Copaxone, see this as an answer to increased earnings pressure of the next few years. Either this purchase or the Mylan deal will give them the breathing room they need. Watch what they say on earnings conference call.
I'm thinking MYL doesn't want TEVA owning any part of their company. They'll strike a price to acquire the shares back.
Might be right. They have never had direct competition on their branded cash cow Copaxone- now there is. The arrogance i see in the fact that they raised their prices twice in the last year for it speaks volumes to a market willing to embrace a generic. These guys have been fisting the MS community. The next year should be interesting.
They might just turn around and buy it anyways or it's a drop in the bucket for the worlds largest supplier of generics !!!!
Sentiment: Strong Buy